Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States

Figure 2 Temporal trends in delivery of radiotherapy technique.

Read More>>

Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy

Figure 3 Multispectral fluorescent IHC staining (200×) and image analysis using a panel of markers including CD68, PD-L1, CK20, and DAPI on pretreatment tumor specimens in a responder to PD-1 blockade (top row) and a nonresponder to PD-1 blockade (bottom row) identified that PD-L1 expression was observed primarily on non-tumor cells, specifically on CD68+ tumor-associated macrophages. Case (top row) from a MSI-H mCRC patient with response to pembrolizumab and (bottom row) from a MSI-H mCRC patient with no response to pembrolizumab.

Read More>>

Evolving Role of Immune-oncology Therapeutics in GI Malignancies edited by Dr. Devalingam Mahalingam

In recent years, we have witnessed immunotherapy-based agents transform how we manage patient’s malignant melanoma, non-small cell lung cancer, genitourinary cancers, head and neck cancers and Hodgkin’s lymphoma to list a few. Unfortunately, the progress of immunotherapy-based agents in GI cancers has been slow, although in 2017 we have seen approval of (I) Nivolumab/Pembrolizumab for patients with metastatic CRC with high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR), (II) Pembrolizumab for patients with advanced gastric and GE junction tumors, who have failed at least two lines of chemotherapy and express PD-L1 protein, (III) Nivolumab for the treatment of patients with HCC following prior sorafenib, regardless of PD-L1 status.

Read More>>

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

Figure 2 Overall survival. Time on study ranged from 0–8.6 months (median 1.3 months, 95% CI, 1–1.6 months). All patients have died, with survival ranging from 0.4 months to 26.8 months. The median PFS is 2.4 months (95% CI, 2.1–3.9 months) and median survival is 5.7 months (95% CI, 3.8–8.2 months). The 1-year survival rate was 20% (95% CI, 7–33%) for all 35 patients.

Read More>>

Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography

Table 3 Multivariate analysis of factors predicting T-staging accuracy of endoscopic ultrasonography 

Read More>>

Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer—patterns of care and overall survival

Figure 1 Utilization of SBRT and CFRT from 1998 to 2012 for individuals with locally-advanced pancreatic cancer. SBRT, stereotactic body radiotherapy; CFRT, conventionally fractionated radiotherapy.

Read More>>

Adjuvant chemotherapy and outcomes in esophageal carcinoma

Figure 2 Overall Survival and recurrence free survival comparisons for the propensity score matched cohort. (A) OS comparison for the propensity score matched cohort. The median OS was 2.7 years (CI, 1.6–3.7) in the group that received adjuvant chemotherapy and 2.8 years (CI, 2.0–3.6) in the group that did not receive any postoperative therapy (P=0.421)...

Read More>>

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice

Table 1 Randomized phase III trials that constitute the IDEA project

After long anticipation, the preliminary results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study were reported at the American Society of Clinical Oncology on June 4, 2017.

Read More>>

The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis

Figure 3: Overall survival: 5-year overall survival rates were: 43.3% (95% CI: 30.1, 62.3%) (no RT) vs. 58.3% (95% CI: 43.4%, 78.2%) (RT). The 5-year disease-specific survival rates were 49.6% (95% CI: 35.5%, 69.4%) (no RT) vs. 60.5% (95% CI: 45.0%, 81.33%) (RT). RT, radiotherapy.

Read More>>

A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma

Figure 1: Kaplan-Meier estimates for (A) recurrence-free survival (RFS) and (B) overall survival (OS) for patients stratified by margin clearance (MC) following pancreaticoduodenectomy (PD)

Read More>>